Want to see FR:EQS full AI Analyst Report?
Top Page
Equasens
(EQS)
Select Model
Select Model
Rating:73Outperform
Price Target:
€38.00
▲(16.21% Upside)
Action:Reiterated
Date:08/07/26
The score is driven primarily by solid financial performance (durable profitability, healthy returns, and an improving balance sheet) and supportive valuation (low P/E and attractive dividend yield). These positives are tempered by weaker technical positioning (below key longer-term moving averages and negative MACD) and recent concerns around slowing/uneven growth and declining free cash flow growth.
Positive Factors
Profitability & Returns
Equasens' sustained high-teens net margin and ~20% operating margin with ROE near 14.9% indicate durable operating profitability and efficient capital use. This supports long-term cash generation, funds reinvestment into products, and resilience through cyclical pressure.
Negative Factors
Declining Free Cash Flow Growth
Although absolute FCF is positive, multi-year negative free cash flow growth signals deteriorating cash conversion or rising investment needs. Persisting decline could limit reinvestment capacity and shareholder returns, pressuring long-term strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability & Returns
Equasens' sustained high-teens net margin and ~20% operating margin with ROE near 14.9% indicate durable operating profitability and efficient capital use. This supports long-term cash generation, funds reinvestment into products, and resilience through cyclical pressure.
Read all positive factors
Equasens (EQS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€488.17M
Dividend Yield4.31%
Average Volume (3M)19.95K
Price to Earnings (P/E)12.5
Beta (1Y)0.56
Revenue Growth9.12%
EPS Growth8.55%
CountryFR
Employees1,462
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)2.59
Shares Outstanding15,174,125
10 Day Avg. Volume30,556
30 Day Avg. Volume19,955
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)2.68
Price to Sales (P/S)2.86
P/FCF Ratio14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.02
Revenue Forecast (FY)€261.07M
Equasens Business Overview & Revenue Model
Company Description
Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their ne...
How the Company Makes Money
Equasens primarily makes money by selling and supporting healthcare software used by pharmacies and other healthcare professionals. Its revenue model is mainly based on (1) recurring software revenues such as subscriptions, software licenses, and ...
Equasens Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
80
Positive
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 236.52M | 216.75M | 219.79M | 214.07M | 193.07M |
| Gross Profit | 49.74M | 47.13M | 56.66M | 59.01M | 53.81M |
| EBITDA | 65.30M | 59.44M | 68.63M | 68.53M | 61.59M |
| Net Income | 39.33M | 36.23M | 47.05M | 46.25M | 39.12M |
Balance Sheet | |||||
| Total Assets | 439.00M | 398.01M | 394.05M | 350.81M | 329.95M |
| Cash, Cash Equivalents and Short-Term Investments | 87.10M | 40.16M | 54.69M | 68.01M | 64.79M |
| Total Debt | 53.80M | 48.45M | 69.27M | 66.52M | 84.06M |
| Total Liabilities | 176.00M | 157.32M | 166.42M | 154.01M | 164.72M |
| Stockholders Equity | 252.28M | 231.51M | 219.28M | 189.78M | 159.00M |
Cash Flow | |||||
| Free Cash Flow | 47.10M | 35.91M | 43.17M | 46.75M | 37.09M |
| Operating Cash Flow | 59.20M | 47.55M | 61.59M | 56.98M | 47.52M |
| Investing Cash Flow | -12.10M | -13.90M | -50.53M | -20.82M | -36.19M |
| Financing Cash Flow | -48.50M | -36.20M | -16.09M | -39.88M | -9.80M |
Equasens Technical Analysis
Negative
32.70
Price Trends
33.60
Negative
34.95
Negative
36.44
Negative
Market Momentum
-0.34
Positive
36.85
Neutral
8.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EQS, the sentiment is Negative. The current price of 32.7 is below the 20-day moving average (MA) of 33.55, below the 50-day MA of 33.60, and below the 200-day MA of 36.44, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 36.85 is Neutral, neither overbought nor oversold. The STOCH value of 8.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EQS.
Equasens Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €488.17M | 12.55 | 16.31% | 4.31% | 9.12% | 8.55% | |
60 Neutral | €141.80M | -9.66 | -5.44% | 2.17% | -0.81% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €196.11M | 41.70 | 2.71% | ― | 9.08% | 21.19% | |
50 Neutral | €201.19M | -3.57 | 90.10% | ― | 1.79% | 15.89% |
* General Sector Average
FR:EQS
Equasens
32.50
-10.29
-24.05%
FR:ALCGM
Cegedim
10.34
-0.06
-0.58%
FR:ALERS
Eurobio-Scientific SA
19.60
-5.65
-22.38%
FR:ALMDT
Median Technologies
4.11
0.60
16.95%
FR:ALBIO
Biosynex SA
0.89
-0.29
-24.41%
FR:ABLD
ABL Diagnostics SA
2.42
-2.28
-48.46%
Equasens Corporate Events
Equasens H1 2026 Revenue Rises on Recurring Digital Health Services
Jul 30, 2026
Equasens delivered a robust first half of 2026, increasing group revenue to €124.5m, up 7.3% year‑on‑year, with organic growth of 1.4% and annual recurring revenue reaching €111.1m, an 8.8% rise versus mid‑2025. The m...
Equasens Details H1 2026 Activity on New Share Liquidity Contract
Jul 28, 2026
Equasens has reported on the status of its liquidity contract following the appointment of NATIXIS ODDO BHF as new provider from 1 April 2026, replacing Gilbert Dupont. As of 30 June 2026, the liquidity account held 4,607 shares and EUR 314,173 in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.